RESUMEN
OBJECTIVES: To evaluate the contribution of cysK and cysM to the fluoroquinolone (ofloxacin) antibiotic resistance in Salmonella Typhimurium, and their impact on H2S and cysteine production through targeted mutagenesis. METHODS: Salmonella Typhimurium 14028s and its cysK and cysM mutants were tested for their susceptibility to ofloxacin, as determined by a broth microdilution test (to determine the MIC) and survival curves. H2S levels were measured by the Pb(AC)2 method and cysteine levels were determined using 5,5-dithio-bis-2-nitrobenzoic acid. DNA damage induced by antibiotic treatment was determined by PFGE. Finally, expression of cysK and cysM genes under antibiotic treatment was determined by real-time reverse transcription PCR. RESULTS: As determined by MIC, the ΔcysK strain was more resistant to ofloxacin, a reactive oxygen species (ROS)-producing fluoroquinolone, than the WT and ΔcysM strains, which correlates with survival curves. Moreover, the ΔcysK strain exhibited higher H2S levels and lower cysteine levels than the WT strain. Finally, the ΔcysK strain exhibited lower DNA damage upon challenge with ofloxacin than the WT and ΔcysM strains. These results are in accordance with lower expression of cysK under ofloxacin treatment in the WT strain. CONCLUSIONS: This work demonstrated that cysteine metabolism in Salmonella Typhimurium modulated H2S levels, conferring resistance to second-generation fluoroquinolones.
Asunto(s)
Antibacterianos/metabolismo , Cisteína Sintasa/metabolismo , Cisteína/metabolismo , Farmacorresistencia Bacteriana , Fluoroquinolonas/metabolismo , Sulfuro de Hidrógeno/metabolismo , Salmonella typhimurium/efectos de los fármacos , Antioxidantes/metabolismo , Cisteína Sintasa/genética , Fluoroquinolonas/antagonistas & inhibidores , Eliminación de Gen , Perfilación de la Expresión Génica , Humanos , Pruebas de Sensibilidad Microbiana , Viabilidad Microbiana/efectos de los fármacos , Ofloxacino/antagonistas & inhibidores , Ofloxacino/metabolismo , Salmonella typhimurium/crecimiento & desarrollo , Salmonella typhimurium/metabolismo , Salmonella typhimurium/fisiologíaRESUMEN
Copper(II) complexes of fluoroquinolone antibacterial agents levofloxacin (LEV) and sparfloxacin (SPAR), containing or not a nitrogen donor heterocyclic ligand, 2,2'-bipyridine (bipy) or 1,10-phenathroline (phen), were prepared and characterized. The complexes are of the type [CuCl(2)(H(2)O)(L)], [CuCl(bipy)(L)]Cl and [CuCl(2)(phen)(L)], where L = LEV or SPAR. The data suggest that LEV and SPAR act as zwitterionic bidentade ligands coordinated to Cu(II) through the carboxylate and ketone oxygen atoms. The electron paramagnetic resonance spectra of the [CuCl(bipy)(L)]Cl and [CuCl(2)(phen)(L)] complexes (L = LEV and SPAR) in aqueous and DMSO solutions indicate mixture of mononuclear and binuclear forms. The Cu(II) complexes, together with the corresponding ligands, were evaluated for their trypanocidal activity in vitro against Trypanosoma cruzi, the causative agent of Chagas disease. The assays performed against bloodstream trypomastigotes showed that all complexes were more active than their corresponding ligands. Complexes [CuCl(2)(phen)(LEV)] and [CuCl(2)(phen)(SPAR)] were revealed, among all studied compounds, to be the most active with IC(50) = 1.6 and 4.7 µM, respectively, both presenting a superior effect than benznidazole. The interactions of fluoroquinolones and their Cu(II) complexes with calf-thymus DNA were investigated. These compounds showed binding properties towards DNA, with moderated binding constants values, suggesting that this structure may represent a parasite target.
Asunto(s)
Cobre/farmacología , Fluoroquinolonas/farmacología , Compuestos Organometálicos/farmacología , Tripanocidas/farmacología , Trypanosoma cruzi/efectos de los fármacos , Animales , Bovinos , Cobre/metabolismo , ADN/efectos de los fármacos , ADN/metabolismo , Espectroscopía de Resonancia por Spin del Electrón , Fluoroquinolonas/química , Fluoroquinolonas/metabolismo , Técnicas In Vitro , Levofloxacino , Ofloxacino/química , Ofloxacino/metabolismo , Ofloxacino/farmacología , Compuestos Organometálicos/química , Compuestos Organometálicos/metabolismo , Espectrofotometría Ultravioleta , Tripanocidas/química , Tripanocidas/metabolismoRESUMEN
Carbomer hydrogels 971pNf, 934pNf and 940Nf loaded with ofloxacin were characterized and their antimicrobial properties evaluated. bactericidal profiles show improved efficacy and prolonged activity exhibited by ofloxacin-containing hydrogels against Pseudomonas aeruginosa. Analysis of bactericidal index (BI) values after a short time of drug exposure confirms the higher potency of hydrogels compared with that of ofloxacin. Increased BI values observed after 24 h indicate prolonged action against the microorganisms evaluated. The bacterial uptake of ofloxacin from hydrogels was higher than that obtained with a solution of free ofloxacin in both fluoroquinolone-sensitive and -resistant P. aeruginosa. The improved uptake in fluoroquinolone-resistant isolates was correlated with the viscosity of hydrogels. The performance of hydrogels seems to be related to their bioadhesive properties that allow prolonged contact time and the release of an effective amount of drug close to bacterial cells. Hence, hydrogels could be used in the development of more effective formulations for topical administration of antibiotics. Improved performance of an old antibiotic can preserve the use of new generation fluoroquinolones.
Asunto(s)
Antibacterianos/metabolismo , Antibacterianos/farmacología , Ofloxacino/metabolismo , Ofloxacino/farmacología , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/efectos de los fármacos , Resinas Acrílicas , Adhesividad , Ciprofloxacina/metabolismo , Ciprofloxacina/farmacología , Fluoroquinolonas/metabolismo , Fluoroquinolonas/farmacología , Humanos , Hidrogeles , Pruebas de Sensibilidad Microbiana , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/aislamiento & purificación , Pseudomonas aeruginosa/metabolismo , Reología , ViscosidadRESUMEN
Los microorganismos involucrados en infecciones del tracto respiratorio alto y bajo, incluyen tanto bacterias "típicas" tales como Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes y Moraxella catarrhalis, y bacterias "atípicas", como Mycoplasma pneumoniae, Chlamydia pneumoniae y Legionella pneumophila. El primer grupo ha adquirido resistencia, tanto a nivel mundial como nacional, a los antimicrobianos de uso habitual en el tratamiento de estas infecciones, como son penicilina, ampicilina, cotrimoxazol, cefuroxima y cefotaxima, entre otros. Debido a lo anterior, se han desarrollado nuevas moléculas siendo una de ellas levofloxacino, una nueva quinolona, levoisómero de D-L racemato de ofloxacino. Este compuesto posee un amplio espectro "in vitro" contra bacteria Gram positivas, incluyendo S. pneumoniae resistente a penicilina, bacterias Gram negativas, bacterias atípicas y algunas bacterias anaerobias. Su biodisponibilidad en forma oral es de 100 por ciento. Es metabolizada en el hígado y su excreción a nivel renal es de 80 por ciento. En estudios clínicos levofloxacino ha demostrado eficacia y seguridad incluso con erradicación microbiológica demostrada en infecciones respiratorias adquiridas en la comunidad, lo que la convierte en una alternativa real de tratamiento